Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 8, 2015

Primary Completion Date

October 25, 2017

Study Completion Date

September 3, 2019

Conditions

Metastatic Castrate-Resistant Prostate Cancer

Interventions

DRUG

Alobresib

Tablet administered orally once daily.

DRUG

Enzalutamide

Capsules administered orally once daily.

Trial Locations (4)

Baltimore

Durham

San Francisco

Boston